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Abstract
Various single or multi-modality therapeutic options 
are available to treat pain of bone metastasis in pa-
tients with prostate cancer. Different radionuclides that 
emit β-rays such as 153Samarium and 89Strontium and 
achieve palliation are commercially available. In con-
trast to β-emitters, 223Radium as a a-emitter has a short 
path-length. The advantage of the a-emitter is thus a 
highly localized biological effect that is caused by radia-
tion induced DNA double-strand breaks and subsequent 
cell killing and/or limited effectiveness of cellular repair 
mechanisms. Due to the limited range of the a-particles 
the bone surface to red bone marrow dose ratio is also 
lower for 223Radium which is expressed in a lower my-
elotoxicity. The a emitter 223Radium dichloride is the 
first radiopharmaceutical that significantly prolongs 
life in castrate resistant prostate cancer patients with 
wide-spread bone metastatic disease. In a phase Ⅲ, 
randomized, double-blind, placebo-controlled study 921 
patients with castration-resistant prostate cancer and 
bone metastases were randomly assigned. The analysis 
confirmed the 223Radium survival benefit compared to 
the placebo (median, 14.9 mo vs  11.3 mo; P  < 0.001). 
In addition, the treatment results in pain palliation and 
thus, improved quality of life and a delay of skeletal 
related events. At the same time the toxicity profile of 
223Radium was favourable. Since May 2013, 223Radium 
dichloride (Xofigo®) is approved by the US Food and 
Drug Administration.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The incidence rate of prostate cancer world-
wide is high. Ninety percent of patients dying of 
prostate cancer have bone metastases with varying 
symptoms which are significantly impairing their qual-
ity of life. 223Radium is the first therapeutic that results 
in a survival benefit for patients with bone metastatic, 
castrate resistant prostate cancer. 223Radium was also 
associated with low myelosuppression rates and fewer 
adverse events.This article provides an overview of the 
pre-clinical and clinical trials with 223Radium. 
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INTRODUCTION
According to estimates from the International Agency 
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for Research on Cancer (IARC, GLOBOCAN 2008), 
the incidence rate of  prostate cancer worldwide is 13.6 
per 100000 inhabitants per year, with a mortality of  6.1 
per 100000 per year[1]. The incidence rate differs quite 
significantly among the various regions of  the world. It 
is lowest in Central Asia with 4.1 per 100000 and high-
est in Australia/New Zealand with 104 per 100000[1]. 
Ninety% of  patients dying of  prostate cancer have bone 
metastases[2]. Patients with bone metastases have varying 
symptoms such as pain, pathological fractures, neurologi-
cal disorders, spinal cord compression, and bone marrow 
failure, which are significantly impairing their quality of  
life[3,4]. 
An optimal therapy leads to pain reduction, improved 
quality of  life, and prolonged survival. Various single or 
multi-modality therapeutic options are available to treat 
bone pain. These include analgesics, hormone therapy, 
chemotherapy, external beam radiation, biphosphonates, 
or β-emitting radionuclides. 
Combined pain medication and external radiotherapy 
result in pain relief  in up to 70% of  patients with local-
ized pain[5]. However, external radiotherapy is only pos-
sible to a limited extent in patients with multiple bone 
metastases and diffuse bone pain.
Different radionuclides that emit β-rays such as 
153Samarium and 89Strontium and achieve palliation are 
commercially available. 89Strontium is a pure β-emitter 
with a relatively long half-life of  50.5 d. 153Samarium has 
a shorter half-life of  1.9 d and emits β-rays in addition to 
γ-rays (Table 1). Thus, imaging of  the skeletal samarium 
distribution post therapy is feasible. In more than half  of  
the cases, administration of  these radiopharmaceuticals 
results in a decrease of  pain[6-8]. Yet, an effect of  this ther-
apy on patient survival is not investigated in randomised 
phase Ⅲ studies. 
β-emitters with a low linear energy transfer (LET) 
and a long β-range can lead to a high radiation burden of  
the bone marrow and thus carry the risk of  a significant 
myelosuppression. This bone marrow suppression may 
be dose limiting. 
In contrast to β-emitters, a-emitters have a short 
path-length of  less than 0.1 mm which increases the local 
anti-tumour effect without affecting the bone marrow. 
The a-emitter 223Radium dichloride is the first radio-
pharmaceutical that significantly prolongs life in castrate 
resistant prostate cancer patients with wide-spread bone 
metastatic disease. Radium-223 has been developed by 
the Norwegian company Algeta ASA, in a partnership 
with Bayer, under the trade name Xofigo®. 223Radium 
dichloride is approved by the US Food and Drug Admin-
istration (FDA) and by the European Commission (EC).
This article provides an overview of  the pre-clinical 
and clinical trials with 223Radium. 
PATIENT EXPOSURE
Lassmann et al[9] provided a comprehensive dosimetry 
calculation of  absorbed organ doses after intravenous 
administration of  223Radium chloride for 25 organs or 
tissues. Bone surface and red bone marrow show the 
highest dose coefficients followed by liver, colon, and in-
testines. Six cycles of  223Radium at 0.05 MBq/kg[10] (corre-
sponding to 21 MBq for a 70 kg patient), the absorbed a 
dose to the bone surface was calculated at around 16 Gy 
with a dose of  approximately 1.5 Gy to the bone marrow. 
Patient-specific dosimetry data have not been published 
yet.
PHARMACOKINETICS AND PRECLINICAL 
STUDIES
Radium was discovered in December 1898 by the physi-
cist Marie Curie and her husband Pierre Curie. 223Radium 
decays originates from uranium and has a natural decay 
balance with uranium. The a-emitter 223Radium is water 
soluble as 223Radium chloride. 223Radium can be relatively 
easily gained from 227Actinium through a cation exchange 
system. Due to the long half-life of  227Actinium (21.7 
years), it could potentially be used as a long-term genera-
tor.
223Radium has a half-life of  11.4 d (Table 1) and de-
cays via seven daughter nuclides into stable 207Lead-207. 
The half-life of  the daughter nuclides ranges from sec-
onds to minutes. During the decay of  223Radium, approxi-
mately four a particles and two β particles (electrons) are 
released. The combined energy of  the particles emitted 
during the decay chain of  223Radium and its daughter 
nuclides is 27.5 MeV, with a-particles emitting 95.3% of  
the energy and β-particles emitting 3.6%. One point one 
percent are emitted as gamma rays.
Because of  the electric charge and the relatively high 
mass of  4u, a-particles have a very low penetration 
depth in organic matter which ranges from 40 to 100 
µm which approximately equals the size of  micro me-
tastases. a-particles produce high-linear energy-transfer 
(LET) radiation. The advantage of  the a-emitter is thus 
a highly localized biological effect that is caused by radia-
tion induced DNA double-strand breaks and subsequent 
cell killing and/or limited effectiveness of  cellular repair 
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Table 1  Physical characteristics of 89Strontium, 153Samarium and 223Radium
Radionuclide Half-life Maximum energy (MeV) Mean energy (MeV) Maximum range y-Emission (keV)
89Sr 50.5 d 1.4 (β) 0.583 (β) 7 mm None
153Sm   1.9 d 0.81 (β) 0.229 (β) 4 mm 103
223Ra 11.4 d 5.78 (a) average - < 10 µm 154
mechanisms.
The penetration depth into the surrounding tissue 
of  the β-particles is higher than with 223Radium (Table 
1). Due to the limited range of  the a-particles the bone 
surface to red bone marrow dose ratio is also lower for 
223Radium which is expressed in a lower myelotoxicity of  
223Radium as compared to the “traditional” radiopharma-
ceuticals. 
As a calcium analogue, 223Radium dichloride is ab-
sorbed by the bone after intravenous injection without 
the necessity of  a carrier. Initially, approximately 25% 
of  the injected 223Radium dichloride is bound to the 
bone surface and from there quickly absorbed into the 
bone volume or returned into blood[9]. Eighty percent 
of  the activity is transferred from the exchangeable 
bone volume back to the bone surface at a biological 
half-life of  30 d. The amount of  223Radium dichloride 
that the bone absorbs depends on the regional bone 
metabolism. The target of  223Radium dichloride in the 
bone is calcium hydroxylapatite. The radiopharmaceuti-
cal accumulates in regions of  osteoblast activity, there-
fore allowing the simultaneous treatment of  multiple 
bone metastases. In addition to the bones 223Radium di-
chloride is mainly absorbed from blood into soft tissue, 
including the liver. Its excretion is predominantly via the 
intestines, i.e., the feces. Renal excretion is minimal. In 
contrast, 153Samarium and 89Strontium undergo predom-
inantly renal excretion thereby increasing the probability 
of  renal toxicity.
Because of  its very limited tissue penetration the en-
vironmental risk of  223Radium application is minimal if  
existent at all. Thus, 223Radium dichloride can be admin-
istered safely in an outpatient setting. 
In animal experimental studies, 223Radium had the 
same bone distribution as 89Strontium which suggested 
that a therapeutically relevant dose of  223Radium could 
be applied to bone metastases[11]. In addition, 223Radium 
had a lower myelotoxicity than β-emitters[11]. Rats which 
received chemotherapy and had biphosphonate resistant 
bone metastases, showed a longer survival rate when they 
were treated with 223Radium[12]. This suggested that 223Ra-
dium may not only be used for palliation but may in fact 
prolong life.
PHASE Ⅰ STUDY
The pharmacokinetics, pharmacodynamics, and biodistri-
bution were investigated in a phase Ⅰ study in 10 patients 
with bone metastatic prostate cancer[13]. Three patients 
received injections of  50 kBq/kg radium, another three 
received 100 kBq/kg radium, and 4 patients received 250 
kBq/kg. After 6 wk, 6 of  the 10 patients had another 
injection of  50 kBq/kg. A rapid clearance of  223Radium 
from the blood was observed whereby only 0.5% of  
223Radium remained in the blood after 24 h. On aver-
age, 52% of  the 223Radium was cleared via the intestines, 
which was the main route of  excretion of  223Radium. The 
excretion via the kidneys was relatively low with a mean 
of  4%. No dose limiting toxicity could be verified. 
In another phase Ⅰ study, a total of  25 patients with 
bone metastatic prostate cancer (n = 15) and breast 
cancer (n = 10) received a single dose of  250 kBq/kg 
223Radium (46, 93, 163, 213, or 250 kBq/kg)[14]. The goal 
of  this dose escalation study was to investigate the safety 
profile and the pain response to 223Radium. The pain 
scale was documented before the first injection and at 1, 
4, and 8 wk after the injection. In addition, in 6 patients 
the distribution of  the daughter nuclide 219Radium was 
imaged with a gamma camera and compared to the pre-
therapeutic bone scintigraphy. 
The patients exhibited mild and reversible myelosup-
pression. In one patient, a grade 1 thrombocytopenia was 
observed; 2 patients had a grade 3 neutropenia, and 3 pa-
tients showed a grade 3 leukopenia. Four weeks after the 
injection of  223Radium a pain reduction was observed in 
most patients (60%). 24 h after the injection, the activity 
of  223Radium rapidly decreased to below 1% (redundant). 
Thus, 223Radium was well tolerated at therapeutically rel-
evant doses. The pre- and post-therapeutic gamma camera 
images showed a good correlation with the 223Radium ac-
cumulation in bone metastases.
PHASE Ⅱ STUDY
In a randomized, double-blind multicentre phase Ⅱ study 
the effect of  the repeated administration of  223Radium 
was investigated in patients with symptomatic hormone 
refractory metastatic prostate cancer. Inclusion criteria 
were multiple bone metastases or a painful osseous lesion 
with two consecutive rising PSA values[15]. The endpoints 
of  the study were the efficacy of  223Radium with respect 
to the decrease of  bone-specific alkaline phosphatase 
(ALK) concentration and the time to the occurrence 
of  a skeletal event. All patients also underwent external 
beam radiation. Sixty-four patients were recruited of  
whom 33 received external beam radiation and 223Radium 
while 31 received external beam radiation and placebo 
(saline). Patients received up to 4 injections of  50 kBq/kg 
223Radium or placebo at intervals of  4 wk. Eight patients 
in the 223Radium group and 21 patients in the placebo 
group completed the protocol. The study demonstrated 
an excellent safety profile for 223Radium. There were no 
differences in haemotoxicity between the groups and no 
patient in the 223Radium group terminated the study due 
to treatment related toxic effects. In the 223Radium group, 
3 patients had a grade 2/3 neutropenia, which, however, 
was reversible.
In addition, there was evidence of  biologic effects 
and efficacy with 223Radium. Patients in the 223Radium 
arm had a significantly greater reduction in bone-ALP 
(-65.6%, P < 0.0001) than those in the placebo group 
(-9.3%). The median time to skeletal related events was 
124 wk in the 223Radium group vs 11 wk in the placebo 
arm. The median time until PSA progression was 126 wk 
in the 223Radium group vs 8 wk in the placebo group (P 
=  0.048). Four weeks after the last injection, the median 
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Patients were included in the study when they showed 
two or more bone metastases on skeletal scintigraphy, 
had no visceral metastases, and had been treated with 
docetaxel or if  they were unable to receive docetaxel (Fig-
ure 1). 
The patients were randomized in a ratio of  2:1 and 
received intravenous injections of  223Radium (at a dose of  
50 kBq per kilogram of  body weight) or saline injections 
as placebo. Patient received 6 injections in 4-wk intervals. 
Each patient was provided with the best standard of  care 
including local external-beam radiation therapy or treat-
ment with glucocorticoids, antiandrogens, ketoconazole, 
or estrogens. Chemotherapy, hemibody external radio-
therapy, and other systemic radionuclides were not per-
mitted. 
The primary end point was overall survival, defined 
as the time from randomization to the date of  death, re-
gardless of  cause. The main secondary end points were 
the time to an increase in the total ALP level, a total 
alkaline phosphatase response, the time to the first symp-
tomatic skeletal event, normalization of  the total alkaline 
phosphatase level and the time to an increase in the PSA 
level.
The study was designed to provide a statistical power 
of  90% to detect a hazard ratio of  0.76 for the risk of  
death in the 223Radium group vs the placebo group with 
a two-sided alpha significance level of  0.05. In total, 614 
patients were enrolled in the 223Radium group and 307 
patients in the placebo group. The patients were enrolled 
in 136 study centres in 19 countries. The baseline patient 
characteristics in both groups were largely identical. 
A pre-defined interim analysis was conducted after 
314 deaths had occurred to assess the effect of  223Radium 
on the primary end point (overall survival). On the basis 
of  this interim analysis, which showed a survival advan-
tage with 223Radium and an acceptable safety profile, early 
discontinuation of  the trial and crossover from placebo 
to 223Radium was recommended. The authors report in 
this study the results of  an updated descriptive analysis 
of  the efficacy and safety data, performed when 528 
deaths had occurred, before any crossover treatment with 
223Radium was administered.
The median overall survival was 14.9 mo in the 223Ra-
dium group and 11.3 mo in the placebo group. The mor-
tality risk was 30% lower in the 223Radium group than in 
the placebo group (P < 0.001). In total 528 patients died; 
333 of  the 614 patients in the 223Radium group (54%) 
and 195 of  the 307 patients in the placebo group (64%). 
A secondary endpoint also confirmed the superiority of  
223Radium over the best standard of  care. The time to 
the first symptomatic skeletal event was 15.6 mo in the 
223Radium group vs 9.8 mo in the placebo group (P < 
0.001). The time to increases in the total ALP (P < 0.001) 
and PSA levels (P < 0.001) was significantly longer in the 
223Radium group. Finally, a significantly larger proportion 
of  patients in the 223Radium group showed a response 
of  the total ALP and PSA levels (≥ 30% reduction, P < 
0.001). Sixteen and 24 wk after initiation of  223Radium 
relative change of  the PSA was -23.8% in the 223Radium 
arm, vs +44.9% in the placebo group (P = 0.003). Im-
portantly, there was a trend toward improved survival in 
the 223Radium group (65.3 wk) vs the placebo group (46.4 
wk; P = 0.066). Thus, 223Radium was tolerated, reduced 
serum ALP levels and tended to improve survival. In an 
additional study, the same authors published the 24 mo 
follow-up of  the patients and confirmed the results of  
the previous study[16]. They confirmed the excellent safety 
profile and demonstrated no increased risk for a second-
ary malignancy. A trend towards improved survival was 
again demonstrated (P = 0.056).
The effect of  different dosages of  223Radium on the 
pain reduction was investigated in another randomized 
and double-blinded study, involving 100 patients with 
castration-resistant, bone metastatic prostate cancer[17]. 
More than 50% of  the patients had 20 or more metasta-
ses, or a superscan. The patients received single doses of  
5, 25, 50, or 100 kBq/kg 223Radium. Patients were classi-
fied as responders or non-responders using a bone pain 
index. Already after 2 wk, a significant pain reduction was 
evident (P = 0.35). After 8 wk, 40%, 63%, 56%, and 71% 
of  the patients were classified as responders in the 5, 25, 
50, and 100 kBq/kg groups, respectively. In the group of  
responders the pain was reduced by a mean of  -30, -31, 
-27, and -28 mm [according to the visual analogue scale 
(VAS)]. Furthermore, the favourable safety profile of  
223Radium was confirmed.
PHASE Ⅲ STUDY AND FDA APPROVAL
A recently published phase Ⅲ trial reported the results 
about Xofigo® from the Symptomatic Prostate Cancer 
Patients (ALSYMPCA) study[10]. This multi-national, 
randomized, double-blind study started in 2008 and by 
February 2011 921 patients were enrolled. The goal of  
the study was to compare the efficacy and safety of  223Ra-
dium vs placebo in patients with castration-resistant pros-
tate cancer and bone metastases.
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Figure 1  Sixty-one years old male with a history of high-grade Gleason 9 
prostate cancer, diagnosed 8 years ago, treated with radiation treatment, 
prostatectomy, and androgen deprivation therapy. Patient has significant 
uncontrolled pain throughout the skeleton. Bone scan demonstrates wide 
spread metastatic disease to the skeleton.  
treatment, patients had significantly less pain compared 
to baseline (P < 0.001 and P = 0.001, respectively).
No clear difference in the appearance of  grade 3 and 
4 adverse events (according to the Common Terminol-
ogy Criteria for Adverse Events) was reported between 
the two groups. One patient in each group showed grade 
3 febrile neutropenia. In the 223Radium group one grade 
5 haematologic adverse event (thrombocytopenia) oc-
cured. Serious adverse events that occurred in > 5% of  
the patients in the 223Radium or the placebo group were 
disease progression, bone pain, anaemia, and spinal cord 
compression. Overall the probability for the appearance 
of  adverse events of  all grades was lower in the 223Ra-
dium group than in the placebo group. The quality of  
life (according to the Functional Assessment of  Cancer 
Therapy-Prostate) improved significantly in the 223Radium 
group. 
Because of  the interim analysis of  the ALSYMPCA 
study, 223Radium was approved by the FDA as a treatment 
for patients with bone metastatic castrate-resistant pros-
tate cancer. The approval was given for patients without 
visceral metastases. 
The suggested regimen follows that of  the ALSYMP-
CA study and includes 50 kBq/kg at an interval of  4 wk 
with a maximum of  6 doses. A simultaneous administra-
tion of  223Radium and chemotherapy is not permitted 
outside of  clinical trials because of  the unclear potential 
of  additive effects on myelosuppression. 
With its approval the FDA requested additional trials 
to determine the efficacy and safety of  223Radium when 
given at doses > 50 kBq/kg. The FDA also requested to 
investigate the long term safety, the effects of  223Radium 
on healthy bone marrow and the risk of  the treatment for 
developing secondary malignancies.
CONCLUSION
223Radium is the first therapeutic that results in a survival 
benefit for patients with bone metastatic, castrate resist-
ant prostate cancer. In addition, the treatment results in 
pain palliation and thus, improved quality of  life and a 
delay of  skeletal related events. At the same time the tox-
icity profile of  223Radium was favourable. Thus 223Radium 
may provide a new standard of  care for patients with 
CRPC and bone metastases.
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